Safer CARS.
作者信息
Heslop Helen E
出版信息
Mol Ther. 2010 Apr;18(4):661-2. doi: 10.1038/mt.2010.42.
Abstract
摘要
相似文献
1
Safer CARS.更安全的汽车碰撞减速度限制系统（CARS）
Mol Ther. 2010 Apr;18(4):661-2. doi: 10.1038/mt.2010.42.
2
Is it safer CARs that we need, or safer rules of the road?我们需要的是更安全的汽车，还是更安全的交通规则？
Mol Ther. 2010 Oct;18(10):1742-3. doi: 10.1038/mt.2010.162.
3
The promise and potential pitfalls of chimeric antigen receptors.嵌合抗原受体的前景与潜在风险。
Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25.
4
Armed T cells with CAR for cancer immunotherapy.用于癌症免疫治疗的嵌合抗原受体武装T细胞。
Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.
5
CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.基于 CD3ζ 的嵌合抗原受体通过顺式和反式信号转导机制介导 T 细胞激活：对优化用于过继细胞治疗的受体结构的启示。
Clin Exp Immunol. 2014 Feb;175(2):258-67. doi: 10.1111/cei.12216.
6
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.嵌合抗原受体T细胞与造血细胞移植：如何避免本末倒置。
Biol Blood Marrow Transplant. 2017 Feb;23(2):235-246. doi: 10.1016/j.bbmt.2016.09.002. Epub 2016 Sep 13.
7
CART trials are going ahead.嵌合抗原受体T细胞（CART）试验正在进行中。
Sci China Life Sci. 2017 Nov;60(11):1276-1279. doi: 10.1007/s11427-017-9198-1. Epub 2017 Oct 26.
8
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.嵌合抗原受体修饰 T 细胞治疗实体瘤：现状与展望。
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.
9
At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.床旁病例探讨：嵌合抗原受体（CAR）T 细胞疗法治疗 B 细胞恶性肿瘤。
J Leukoc Biol. 2016 Dec;100(6):1265-1272. doi: 10.1189/jlb.5BT1115-524R. Epub 2016 Jun 27.
10
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.在人类急性髓系白血病小鼠异种移植模型中对嵌合抗原受体T细胞进行优化清除。
Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.
引用本文的文献
1
Phase I/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation: study rational and design.供者来源的抗白血病细胞毒性T淋巴细胞预防儿童单倍体造血干细胞移植后白血病复发的安全性及初步疗效的I/II期临床试验：研究原理与设计
Front Immunol. 2025 Jun 6;16:1601961. doi: 10.3389/fimmu.2025.1601961. eCollection 2025.
2
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.ST3GAL1 和 βII- spectrin 通路控制 CAR T 细胞向靶肿瘤迁移。
Nat Immunol. 2023 Jun;24(6):1007-1019. doi: 10.1038/s41590-023-01498-x. Epub 2023 Apr 17.
3
CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.基于嵌合抗原受体的实体瘤免疫疗法——基于临床的靶抗原综述
Biology (Basel). 2023 Feb 10;12(2):287. doi: 10.3390/biology12020287.
4
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.可离子化脂质纳米颗粒介导的 mRNA 递送至人嵌合抗原受体 T 细胞工程。
Nano Lett. 2020 Mar 11;20(3):1578-1589. doi: 10.1021/acs.nanolett.9b04246. Epub 2020 Feb 5.
5
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.嵌合抗原受体 T 细胞靶向 EGFRvIII 治疗转移性肺癌。
Front Med. 2019 Feb;13(1):57-68. doi: 10.1007/s11684-019-0683-y. Epub 2019 Feb 5.
6
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.共刺激结构域和细胞因子的选择决定了神经母细胞瘤中嵌合抗原受体T细胞的活性。
Oncoimmunology. 2018 Mar 15;7(6):e1433518. doi: 10.1080/2162402X.2018.1433518. eCollection 2018.
7
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.一项针对自体造血细胞移植后复发的难治性血液系统恶性肿瘤的NK-92细胞I期试验显示了安全性和疗效证据。
Oncotarget. 2017 Jul 12;8(51):89256-89268. doi: 10.18632/oncotarget.19204. eCollection 2017 Oct 24.
8
Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.携带抗ERBB2嵌合抗原受体的人CD3 + T细胞在ERBB2过表达的乳腺癌细胞中表现出高效靶向性并诱导细胞凋亡。
Int J Mol Sci. 2017 Sep 8;18(9):1797. doi: 10.3390/ijms18091797.
9
A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.一种基于新型纳米抗体的靶向模块，用于通过模块化单链通用嵌合抗原受体（UniCAR）平台将T淋巴细胞重定向至表达表皮生长因子受体（EGFR）的癌细胞。
Oncoimmunology. 2017 Feb 6;6(4):e1287246. doi: 10.1080/2162402X.2017.1287246. eCollection 2017.
10
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.设计型嵌合抗原受体T细胞（CAR-T）疗法在实体瘤治疗中面临的挑战：25年展望
Cancer Gene Ther. 2017 Mar;24(3):89-99. doi: 10.1038/cgt.2016.82.
本文引用的文献
1
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.采用基因靶向自体T细胞治疗慢性淋巴细胞白血病：一项I期临床试验中意外不良事件的病例报告
Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
2
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.嵌合抗原受体识别 ERBB2 的 T 细胞给药后严重不良事件的病例报告。
Mol Ther. 2010 Apr;18(4):843-51. doi: 10.1038/mt.2010.24. Epub 2010 Feb 23.
3
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.异基因造血细胞移植后针对次要组织相容性抗原的 T 细胞治疗复发白血病。
Blood. 2010 May 13;115(19):3869-78. doi: 10.1182/blood-2009-10-248997. Epub 2010 Jan 13.
4
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.移植受者中预防或治疗 EBV 相关淋巴增殖性疾病的 EBV 特异性 T 细胞输注的长期结果。
Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.
5
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.一种基于赫赛汀的嵌合抗原受体，其信号结构域经过修饰，可提高转导T淋巴细胞的存活率和抗肿瘤活性。
J Immunol. 2009 Nov 1;183(9):5563-74. doi: 10.4049/jimmunol.0900447.
6
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.使用人类和小鼠T细胞受体的基因疗法介导癌症消退，并靶向表达同源抗原的正常组织。
Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.
7
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.白血病患者接受单倍体相合造血干细胞移植后输注自杀基因工程供体淋巴细胞（TK007试验）：一项非随机的I-II期研究
Lancet Oncol. 2009 May;10(5):489-500. doi: 10.1016/S1470-2045(09)70074-9. Epub 2009 Apr 1.
8
Graft-versus-leukemia effects of transplantation and donor lymphocytes.移植及供体淋巴细胞的移植物抗白血病效应
Blood. 2008 Dec 1;112(12):4371-83. doi: 10.1182/blood-2008-03-077974.
9
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.经过基因工程改造以共表达肿瘤特异性受体的病毒特异性T细胞：在神经母细胞瘤患者中的持久性和抗肿瘤活性
Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.
10
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.使用基因改造的自体CD20特异性T细胞对惰性非霍奇金淋巴瘤和套细胞淋巴瘤进行过继性免疫治疗。
Blood. 2008 Sep 15;112(6):2261-71. doi: 10.1182/blood-2007-12-128843. Epub 2008 May 28.
Zotero 插件